Hello,

CADI™ Discovery, the other A.I. for complex diseases, and our team wish you a happy and fruitful new year thinking and acting out of the box!
In 2019, our founding motto: "Understand disease mechanisms first. Adapted treatments will follow." is still highly relevant.

Thinking and acting in an original way, we decided in 2004 to create Bio-Modeling Systems to implement a “SMART STRATEGY”. Profitable since 2006, thanks to our recurrent clients, “Mechanisms-Based Medicine” and CADI™ Discovery have well proven to be the prime avenue for business risk reduction and the development of cost-effective beneficial solutions for patients. Indeed, "correct understanding of disease/disorder mechanisms is the first objective. Finding the most adapted integrated diagnostics, therapies & preventive solutions are the necessary outcomes of the first objective".

For us, Institutions, Foundations, Patients Associations, companies and Individuals who share our vision are the natural partners for trying to solve the challenges of complex diseases through thinking and acting "out of the box".

2018 was a great year for our company, with tangible successes in inflammation, CNS/neurology and metabolism, the three key meta-fields of complex human diseases mechanisms. Among them:

- The Success of GEMMA 14,2 Me H2020 program officially launched on January 1, 2019 addressing autism and microbiota (inflammation, CNS, embryology) with Bio-Modeling Systems being the Integrative Biology partner.
- The new dual therapeutic program for Chronic Fatigue Syndrome (CFS) and Gulf War Syndrome. The project is about to begin clinic validation with the CFS patient Association’s support.
- The new dual therapeutic program for Metabolic Syndrome/Parkinson’s disease that is now completed and ready for clinic validation.
- The very positive evolution of our first therapeutic spin-off in antibiotic resistance in Phase 2 and compassionate use and our first exclusive out-license in CNS to a CEA’s therapeutic spin-off (in Phase 2).
- The publication in Current Opinion in Pharmacology, that explains why and how we invented CADI™ Discovery.

For 2019, in addition to the implementation of our 2018 programs, we've already undertaken some very exciting projects at different stages of development:

- CADI™ model ready for evaluation:
  - Model of Alzheimer’s disease. In its current state, the model describes the causal mechanisms and progression of the disease, producing biomarkers that could predict and increase vigilance against AD in the early stages of its progression. This CADI™ model can already explain 14 key disease components, unifying opposing viewpoints while clarifying much of the inconsistency in the bibliography.

- CAD™I programs ready for construction start-up:
  - Global concept for auto-immune diseases (common mechanisms and differences).
  - Complementary Cancer therapy: Peri-tumoral tissue induction for tumor encystation, leading to metastasis prevention and cancer cells starvation. This dual program should implement novel approaches for harnessing fibrosis.
  - Microbiota dysbiosis real understanding and control.

Today, Bio-Modeling Systems, the world's first Mechanisms-Based Medicine company, has generated 14 successes independently validated by our clients/partners of which: a world's first in neurodegenerative diseases, 1 therapeutic spin-off, 1 exclusive out-license, 4 issued patents, 10 publications (for all details, visit
BMSystems website).

For more information, we invite you to the watch keynote speech, given to 600 life sciences professionals during the BioWinDay conference in Belgium: Artificial Intelligence for Health: Between Dream and Reality.

We warmly invite you to download our Short corporate Presentation or our CADI™ Discovery Concept and POCs Presentation.

Do not hesitate to contact us for more information or any request.

Best regards,

Manuel Gea CEO; VP R&D IT BMSystems
manuel.gea@bmsystems.net

*CADI: Computer Augmented Deductive Intelligence